IQVIA Holdings Inc
Closed
SectorHealthcare
243.22 2.21
Overview
Share price change
24h
Min
233.71
Max
241.78
Income | -17M 258M |
|---|---|
Sales | 217M 4.4B |
P/E Sector Avg | 30.137 57.002 |
EPS | 2.75 |
Profit margin | 5.907 |
Employees | 94,000 |
EBITDA | -18M 790M |
Recommendations | Strong Buy |
|---|---|
12 Months Forecast | +15.54% upside |
Next Earnings | 27 Oct 2026 |
|---|
Market Cap | 4.2B 40B |
|---|---|
Previous open | 241.01 |
Previous close | 243.22 |
IQVIA Holdings Inc Chart
Past performance is not a reliable indicator of future results.
Related News
Peer Comparison
Price change
IQVIA Holdings Inc Forecast
Price Target
By TipRanks
15.54% upside
12 Months Forecast
Average 273.43 USD 15.54%
High 300 USD
Low 240 USD
Based on 16 Wall Street analysts offering 12 month price targets forIQVIA Holdings Inc - Dist in the last 3 months.
Financials
Selling and administration expenses
Operating expenses
Pre-tax profit
Sales
Cost of sales
Gross profit on sales
Interest expense on debt
EBITDA
Operating profit
$
About IQVIA Holdings Inc
IQVIA Holdings Inc. engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions. The Technology & Analytics Solutions segment offers a range of cloud-based applications and related implementation services; real world solutions that enable life sciences and provider customers to generate and disseminate evidence, which informs health care decision making and improves patients' outcomes; and strategic and implementation consulting services, such as advanced analytics and commercial processes outsourcing services. This segment also provides country level performance metrics related to sales of pharmaceutical products, prescribing trends, medical treatment, and promotional activity across various channels, including retail, hospital, and mail order; and measurement of sales or prescribing activity at the regional, zip code, and individual prescriber level. The Research & Development Solutions segment offers project management and clinical monitoring; clinical trial support; strategic planning and design services; and patient and site centric solutions, as well as central laboratory, genomic, bioanalytical, ADME, discovery, and vaccine and biomarker laboratory services. The Contract Sales & Medical Solutions segment provides health care provider and patient engagement services, and scientific strategy and medical affairs services. It serves pharmaceutical, biotechnology, device and diagnostic, and consumer health companies. The company has a collaboration with argenx SE; and a strategic collaboration with NVIDIA Corporation. The company was formerly known as Quintiles IMS Holdings, Inc. and changed its name to IQVIA Holdings Inc. in November 2017. The company is headquartered in Durham, North Carolina.
